SVF
Level D· Preclinical EvidenceAnimal Study

Adipose-derived stem cell exosomes for stress urinary incontinence: a novel in vivo therapeutic approach.

Hamed B., Salem M., Mosbah E., El-Hefnawy A., Khater S., Elmorsy E.

Animal Study on Systemic / IV, published in Int Urol Nephrol (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int Urol Nephrol (2026)
Country
Netherlands
Reported sample size
—
PMID
40615655
DOI
10.1007/s11255-025-04628-6

Abstract (original English)

This study aimed to evaluate the therapeutic effects of adipose tissue-derived stem cell exosomes (ADSCE) in the management of stress urinary incontinence (SUI) using vaginal dilatation-induced acute and chronic SUI models in Sprague-Dawley rats. The model for acute and chronic SUI was established via single and repeated vaginal dilatation, respectively. Mesenchymal cells, mesenchymal stem cells, and exosomes were isolated. Flow cytometry confirmed the mesenchymal identity of isolated stem cells, while exosomal markers (CD9, CD63, CD81) validated successful exosome isolation. Transmission electron microscopy revealed the characteristic nanoscale morphology of exosomes, further supported by energy-dispersive X-ray analysis. Rats were treated with the exosomes locally and vaginally. Therapeutic efficacy was assessed through urodynamic and histopathological analyses. Abdominal leak point pressure (ALPP) was significantly reduced in both acute and chronic SUI models compared to controls (P < 0.0001). ADSCE therapy significantly increased ALPP, with systemic administration demonstrating superior efficacy over local treatment (P < 0.05). Histopathological examination indicated substantial sphincter muscle thinning, edema, and fibrosis in untreated models, while exosome therapy mitigated these pathological changes. Masson's Trichrome staining revealed significant preservation of ureth

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
AnimalsUrinary Incontinence, StressExosomesRats, Sprague-DawleyRatsFemaleAdipose TissueDisease Models, AnimalMesenchymal Stem CellsUrodynamics
Systemic / IV
View on PubMedDOI

Related research